Stockscreener 앱 받기
5.94
3.73%
-0.23
시간 외 거래:
6.02
0.08
+1.35%
전일 마감가:
$6.17
열려 있는:
$6.17
하루 거래량:
12.36M
Relative Volume:
0.55
시가총액:
$2.41B
수익:
$64.60M
순이익/손실:
$-377.75M
주가수익비율:
-3.8323
EPS:
-1.55
순현금흐름:
$-335.64M
1주 성능:
-4.81%
1개월 성능:
-30.12%
6개월 성능:
-9.59%
1년 성능:
-45.90%
1일 변동 폭
$5.84
$6.26
1주일 범위
$5.73
$6.642
52주 변동 폭
$5.60
$12.36
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.94 | 2.41B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.51 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns - Seeking Alpha
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’ - Insider Monkey
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip - MSN
Why Recursion Pharmaceuticals Stock Is Sinking Today - Yahoo Finance
Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus - Insider Monkey
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? - Nasdaq
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip - Benzinga
QRG Capital Management Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Is What Whales Are Betting On Recursion Pharmaceuticals - Benzinga
Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today - MSN
This Biotech Stock Could Be the Best Investment of the Decade - The Globe and Mail
April 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? - MSN
IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (RXRX) Remains Optimistic Despite Q4 Disappointment - TipRanks
TechBio Latest News - substack.com
How To Trade (RXRX) - Stock Traders Daily
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts - Yahoo Finance
Recursion Pharmaceuticals Shares Dip Amid Revenue Timing - TipRanks
Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday - MSN
Rhumbline Advisers Has $2.26 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% on Disappointing Earnings - Defense World
Recursion Pharmaceuticals Inc (RXRX) Q4 2024 Earnings Call Highlights: Strong Financial ... By GuruFocus - Investing.com Canada
Recursion Pharmaceuticals projects $100M synergies in 2025 amid advancing pipeline and partnerships - MSN
Recursion Pharmaceuticals’ Earnings Call Highlights Growth - TipRanks
Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering - Yahoo Finance
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says - Benzinga
Atria Wealth Solutions Inc. Invests $75,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year - Simply Wall St
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down After Earnings Miss - Defense World
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 - MSN
AI Drug Firm Recursion Wants to Be the Amazon Prime of Pharma - Advisor Perspectives
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This FridayArcher Aviation (NYSE:ACHR), Accolade (NASDAQ:ACCD) - Benzinga
Recursion stock holds as Cowen sees merger synergies By Investing.com - Investing.com Canada
Recursion Pharmaceuticals Reports Mixed 2024 Financial Results - TipRanks
Cathie Wood’s ARK ETF bolsters Tempus AI, Recursion stocks By Investing.com - Investing.com Australia
Cathie Wood's ARK ETF bolsters Tempus AI, Recursion stocks - Investing.com
Cathie Wood’s ARK ETF bolsters Tempus AI, Recursion stocks - Investing.com India
Strong Buy Recommendation for Recursion Pharmaceuticals: Leading Techbio Innovator with Robust Financials and Strategic AI Integration - TipRanks
Best Biotech Stocks To Keep An Eye OnFebruary 28th - MarketBeat
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Recursion Pharmaceuticals misses Q4 estimates, shares dip By Investing.com - Investing.com Australia
Recursion Pharmaceuticals misses Q4 estimates, shares dip - Investing.com
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
리커젼 파마 주식 (RXRX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gibson Christopher | Chief Executive Officer |
Mar 06 '25 |
Sale |
6.37 |
20,000 |
127,400 |
1,256,024 |
0.49%
1.87%
자본화:
|
볼륨(24시간):